Velaglucerase alfa

Synonyms :
Imiglucerase, VPRIV

Status : approved

Category

Enzymes

Therapeutic Classification

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

Description

Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.

Used

Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.

Mechanism Of Action

Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.

Dosage

Form Route Strength
Injection, powder, lyophilized, for solution intravenous 2.5 mg/mL
Powder for solution intravenous 400 unit

Half Life

11-12 minutes.

Clearance

Mean clearance ranges from 6.72 to 7.56 mL/min/kg.

Volume of Distribution

The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).

Chemical Classification

Peptides

Organic Compounds

Organic Acids

Carboxylic Acids and Derivatives

Amino Acids, Peptides, and Analogues

Chemical Name

Imiglucerase

Brands

name Dosage form Country
Vpriv powder for solution Canada
Vpriv injection, powder, lyophilized, for solution US

Calculated Property

kind Value Source

Target within organism

  • Glucosylceramidase : in Human